Real-world dosing and persistence of oral treprostinil initiation strategies in patients with pulmonary arterial hypertension

Authors

• Daniel J Lachant, University of Rochester Medical Center
• Ali Ataya, University of Florida Health
• H James Ford, University of North Carolina at Chapel Hill
• Meredith Broderick, United Therapeutics Corporation
• Scott Seaman, United Therapeutics Corporation
• Benjamin Wu, United Therapeutics Corporation
• Murali M Chakinala, Washington University School of Medicine in St. Louis

Journal

Pulmonary Circulation

Publication Date

10-1-2025

Volume

15

Issue

4

First Page

e70227

Document Type

Open Access Publication

DOI

10.1002/pul2.70227

Rights and Permissions

DJ Lachant, A Ataya, H James Ford, M Broderick, S Seaman, B Wu, MM Chakinala, “Real-World Dosing and Persistence of Oral Treprostinil Initiation Strategies in Patients With Pulmonary Arterial Hypertension,” Pulmonary Circulation60 (2025): 1-8, https://doi.org/10.1002/pul2.70227. © 2025 The Author(s). Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Recommended Citation

Lachant, Daniel J; Ataya, Ali; James Ford, H; Broderick, Meredith; Seaman, Scott; Wu, Benjamin; and Chakinala, Murali M, "Real-world dosing and persistence of oral treprostinil initiation strategies in patients with pulmonary arterial hypertension." Pulmonary Circulation. 15, 4. e70227 (2025).
https://digitalcommons.wustl.edu/oa_4/7025

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.